Managing Hereditary Angioedema in a Three-Generation Family: Danazol’s Promise in Resource-Limited Settings
Pradnya M Joshi, Mohd Saeed Siddiqui, Ajinkya Deshmukh, Madhuri B Engade, Mohammad Haseeb, Rishitha Reddy, Supriya Kubde · 2024
Read Managing Hereditary Angioedema in a Three-Generation Family: Danazol’s Promise in Resource-Limited Settings by Pradnya M Joshi, Mohd Saeed Siddiqui, Ajinkya Deshmukh, Madhuri B Engade, Mohammad Haseeb, Rishitha Reddy, Supriya Kubde (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11671118.txt.
Description
Pradnya Joshi and co-authors assess an older drug, danazol, for long-term control of hereditary swelling attacks in India, in work from twenty twenty-four. The disorder causes sudden swelling that can block the throat and kill. First-line modern drugs are hard to get in low-resource settings. Danazol is cheap and widely used there despite known risks. The study follows one family across three generations with the disorder.
Records cover more than twenty affected relatives in the family. Blood tests confirm low levels of the missing control protein. Several relatives died in past throat swelling episodes before treatment. Nine patients take danazol for long-term prevention in the study. Control scores improve clearly, and most report far fewer attacks. Mild side effects such as weight gain appear in some patients. The authors back danazol as a cost-effective option with caution.
Catalog record
| CREATOR | Pradnya M Joshi, Mohd Saeed Siddiqui, Ajinkya Deshmukh, Madhuri B Engade, Mohammad Haseeb, Rishitha Reddy, Supriya Kubde |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |